Atea reports Q2 2026 results, cites C-BEYOND Phase 3 win in hepatitis C

Atea Pharmaceuticals reported financial results for the quarter ended June 30, 2026, and gave a business update on its hepatitis C and hepatitis E programs on August 12, 2026.

In July, the company announced topline results from C-BEYOND, a Phase 3 trial testing the combination of bemnifosbuvir and ruzasvir (BEM/RZR) against sofosbuvir and velpatasvir (Epclusa) in chronic HCV. In the modified intent-to-treat population of 905 patients, BEM/RZR achieved a 93.9% sustained virologic response rate versus 94.8% for SOF/VEL at Week 24, encompassing SVR at 12 weeks, the accepted definition of cure for HCV, in both arms.¹ The trial met its primary endpoint of statistical non-inferiority, with a 95% confidence interval for the difference in SVR rates within the prespecified 5% margin.¹ The company said BEM/RZR was generally safe and well tolerated, with no drug-related serious adverse events or drug-related early treatment discontinuations, and safety was comparable between arms.¹

A second Phase 3 trial, C-FORWARD, is being conducted outside North America. Enrollment was completed in June 2026 with more than 880 patients across 17 countries.¹ Topline results are expected in early Q1 2027.¹ Following the C-BEYOND readout and pending C-FORWARD results, Atea anticipates submitting a new drug application to the FDA in the second quarter of 2027.¹

On hepatitis E, Atea initiated a first-in-human Phase 1 trial of AT-587 in July, focused on immunocompromised patients infected with HEV genotypes 3 or 4.¹

On finances, Atea held $219.5 million in cash and investments as of June 30, 2026, compared with $301.8 million at December 31, 2025.¹ Research and development expenses fell to $28.2 million from $32.3 million a year earlier, driven largely by completion of Week 24 post-treatment visits in C-BEYOND.¹